ResMed Inc.

NYSE:RMD

Medical - Devices

Healthcare
$242.61 +0.85%

+$1.58 today

Market cap
$34.12B
Beta
0.78
P/E (TTM)
18.1
EPS (TTM)
$10.37
Dividend yield
1.28%
52W Low $180.27High $293.81

Volume 1.22M

Average 1.32M

RMD Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

ResMed Inc.NYSE: RMD

Selling, General & Admin · Q4 FY2026 · quarter ended Jun 2026

Selling, general & admin grows in line with its trailing trend

Q4 FY2026 selling, general & admin of $296.28M rose 11.8% year over year, behind the +12.4% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 5.9% from the prior quarter. Over 3 fiscal years it compounded at +8.6% a year.

Context

  • Selling, general & admin amounted to 19.8% of revenue in FY2026, up 0.5 pp from a year earlier.
  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 22 analysts of $1.17B (+4.1%) for the fiscal year ending Jun 2027, a slowdown from the +13.0% reported in FY2026.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$296.28M+5.9% QoQ
Last fiscal yearJun 2026
$1.12B+13.0% YoY
LTMJun 2026
$1.11B+12.4% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+11.8%+7.6%-4.2 pp
1 year+13.0%+4.1%-8.8 pp
3-year CAGR+8.6%+5.6%-3.0 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2026
1.12B USD
Year-over-year change
+13.0%
4-year CAGR
+10.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How RMD compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +12.4% is the 2nd highest of 9, against a peer median of +9.0%.
  • Selling, general & admin amounts to 19.7% of revenue for RMD, versus a peer median of 33.3%.
RMD Competitors
Selling, General & Admin for RMD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MDTMedtronic plcLTM Jul 2026$12.18B USD+10.7%+4.2%32.4%
BSXBoston Scientific CorporationLTM Jun 2026$7.16B USD+10.4%+15.1%34.1%
PHGKoninklijke Philips N.V.LTM Jun 2026€4.87B EUR-3.3%-2.1%27.6%
GEHCGE HealthCare Technologies Inc.LTM Jun 2026$4.32B USD+2.0%+5.2%21.3%
ISRGIntuitive Surgical, Inc.LTM Sep 2026$3B USD+29.9%+11.1%25.9%
RMDResMed Inc.LTM Jun 2026$1.11B USD+12.4%+8.6%19.7%
TFXTeleflex IncorporatedLTM Jun 2026$943.66M USD+0.4%-5.9%36.3%
INSPInspire Medical Systems, Inc.LTM Jun 2026$620.31M USD+7.7%+24.9%69.0%
ELMDElectromed, Inc.LTM Mar 2026$41.69M USD+10.2%+13.0%58.1%
Peer median (excluding RMD) —+9.0%+8.1%33.3%

Competitors are the stored peer set for RMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
FY2026
Jun 2026
Revenue3.58B4.22B4.69B5.15B5.65B
Cost of Revenue1.55B1.87B2.03B2.09B2.2B
Gross Profit2.02B2.36B2.66B3.05B3.45B
Gross Margin56.6%55.8%56.7%59.4%61.1%
Research & Development253.58M287.64M307.53M331.28M378.29M
Selling, General & Admin739.37M874M917.14M991.02M1.12B
Operating Expenses1.02B1.22B1.34B1.37B1.54B
Depreciation & Amortization193.84M197.56M216.21M235.81M244.15M
EBITDA1.18B1.36B1.53B1.91B2.15B
EBITDA Margin32.9%32.2%32.7%37.2%38.1%
Operating Income1B1.13B1.32B1.69B1.91B
Operating Margin28.0%26.8%28.2%32.7%33.8%
Interest Income00000
Interest Expense22.31M47.38M45.71M12.61M0
Other Income / Expenses(39.8M)(30.21M)(55.1M)(7.8M)10.96M
Income Before Tax960.48M1.1B1.26B1.68B1.92B
Pre-Tax Margin26.8%26.1%27.0%32.6%34.0%
Income Tax Expense181.05M204.11M243.85M276.84M396.12M
Net Income779.44M897.56M1.02B1.4B1.52B
Net Margin21.8%21.3%21.8%27.2%26.9%
EPS (Basic)5.346.126.949.5510.44
EPS (Diluted)5.306.096.929.5110.40
Weighted Avg Shares146.07M146.77M147.02M146.72M144.71M
Weighted Avg Shares (Diluted)147.04M147.46M147.55M147.34M144.98M

ResMed Inc.

NYSE:RMD

Intrinsic Alpha fair value

Locked

Current Price

$242.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.